Antibodies targeting the NANP/NVDP repeat domain of the Plasmodium falciparum 19 circumsporozoite protein (CSPRepeat) can confer protection against malaria. However, it has 20 also been suggested that this repeat domain exists as a decoy that distracts the immune 21 system from mounting protective responses targeting other domains of CSP. Here we show 22 that B cell responses to the repeat domain are indeed ~10 fold higher than responses to the N-23 and C-terminal regions of CSP after sporozoite immunization. We investigated the role of 24 the number of CSPRepeat-specific naïve precursor B cells and high avidity binding by B cells 25 in driving the immunodominance of the CSPRepeat. Using adoptive transfer of germline 26 precursors specific for the CSPRepeat, we found that increasing precursor number did indeed 27 increase the responses to the repeat region, but not to the detriment of responses to other 28 epitopes. To investigate the role of avid binding by B cells to the CSPRepeat in driving 29 immunodominance we generated CSP9: a truncated CSP molecule with just 9 NANP repeats. 30
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Compared to near full length CSP molecules, CSP9 induced lower BCR signalling in 31
CSPRepeat-specific cells and induced stronger responses to non-repeat epitopes. Finally, we 32 found mice immunized with CSP9 molecules were strongly protected against mosquito bite 33 challenge. Collectively these data demonstrate that the CSPRepeat does function as an 34 immunodominant decoy and that truncated CSP molecules may be a promising avenue for 35 future malaria vaccines. 36
Introduction 45 46 Our most advanced malaria vaccine RTS,S/AS01 aims to induce antibodies that target the repeat region of the circumsporozoite protein (CSP), which covers the surface of the 48 Plasmodium sporozoite (2-4). The rationale for this approach comes from the observation 49 that immunization with radiation attenuated sporozoites confers sterile protection against 50 malaria, and that the humoral response induced by irradiated sporozoites is dominated by 51 anti-CSP antibodies (5) (6) (7) (8) . Early studies demonstrated that monoclonal antibodies (mAbs) 52 targeting the repeat regions of the CSP molecule (CSPRepeat) protected mice against challenge 53 with the rodent parasite P. berghei (9-11). More recently, human monoclonal antibodies 54 targeting the P. falciparum CSPRepeat have also been shown to be protective in preclinical 55 mouse models (12) (13) (14) . 56 57 Despite the protective capacity of CSPRepeat specific Abs, it has also been argued that the 58 CSPRepeat is an immunodominant "decoy" distracting the immune system from making 59 protective responses against other epitopes within CSP or other proteins on the sporozoite 60 surface (15, 16) . Evidence for the immunodominance of the CSPRepeat initially came from 61 early studies which showed that a short (NANP)3 peptide based on this domain could absorb 62 most sporozoite binding activity of sera from hyperimmune individuals (8). In support of the 63 concept that the responses to CSPRepeat are sub-optimal, large amounts of anti-CSPRepeat mAbs 64 are required for protection in preclinical challenge models, while in RTS,S clinical trials 65 protection requires very high amounts (>50 µg/ml) of anti-CSPRepeat antibody (12) (13) (14) 17) . In 66 contrast, antibody responses to other regions of CSP are less well understood. One small 67 epidemiological study associated increased levels of antibodies targeting a truncated CSPNterm 68 peptide with protection from clinical disease (18). Subsequently, a mouse mAb, 5D5, 69 targeting an epitope within the N terminus of CSP was found to be protective against 70 sporozoite challenge (19). More recently, human mAbs targeting the junction between the 71 CSPNterm and CSPRepeat were found to be protective (12, 13) . Antibodies targeting the C-72 terminal domain CSP (CSPCterm) have been associated with protection by the RTS,S vaccine 73 in clinical trials (20, 21), though individual mAbs targeting this domain have not been found 74 to confer protection (14) . 75 76 There has been increased interest in the factors that drive B cell immunodominance and how 77 these can be manipulated for improved vaccination outcomes. Recent findings in influenza 78 and HIV immunology have revealed the existence of broadly neutralising antibodies (bnAbs), 79 however these target rare subdominant epitopes. In HIV it was recently shown that 80 transferred B cells carrying a germline version of the bnAb VRC01 could be induced to 81 compete successfully in germinal centers (GCs) if the number of naïve precursors was 82 artificially increased or if stimulated with a high polyvalent antigen that bound the B cells 83 with greater avidity (22). For influenza it has been shown that broadly neutralizing responses 84 to the stem regions of haemagglutinin (HA) can be favored over responses to the 85 immunodominant -but highly variable -head region by immunization with stem-only 86 constructs, even if delivered alongside full length HA (23). 87 88 Given the highlighted roles for antigen polyvalency and precursor numbers in driving B cell 89 immunodominance, we investigated whether these factors drive the CSPRepeat to be 90 immunodominant. The finding that CSPRepeat can be bound avidly by B cells from a range of 91 immunoglobulin gene families suggested that there may be high numbers of precursors for 92 this domain (12, 13, 24, 25) . More suggestively, we and others have shown that the CSP 93 repeat can be bound by 6 or more specific antibodies (12, 24, 26, 27) , and it has been 94 demonstrated that the repeat can crosslink multiple BCRs to enhance B cell signalling (28) . 95 Accordingly, we tested the roles of these factors in driving the dominance of the S1) (29). At days 4, 7, 14 and 28 post-immunization sera were taken for antibody analysis by 107 ELISA with domain-specific peptides, and spleens were taken for cellular analysis by flow 108 cytometry. IgG responses to the CSPRepeat were significantly higher than responses to either 109 of the other domains, with a significant response developing to the CSPCterm only after 28 110 days ( Fig. 1A) . 111
112
One concern is that ELISA measurements of antibody responses to the different domains are 113 not directly comparable. Therefore, we used tetramer probes to track the total numbers of B 114 cells responding to each domain of CSP over time, and their phenotype by flow cytometry 115 ( Fig. 1B, Fig. S2A ). The response to sporozoites is characterized by an early plasmablast 116 (PB) response that wanes and leaves a prolonged GC reaction (24). Four days after 117 immunization of mice with Pb-PfSPZ, the number of CSPRepeat + CD138 + PBs was ~10 fold 118 higher than the number of CSPNterm + or CSPCterm + PBs (Fig. 1Ci ). By day 7, a pronounced GC 119 reaction developed and the number of CSPRepeat + GL7 + B cells was ~10 fold higher than 120 responses to the other domains, which was sustained until day 28 (Fig 1Cii) . We further 121 analyzed the number of IgD -IgM -(Switched Ig; SwIg) CD38 + memory B cells and found 122 that the immunodominance of the response to the CSPRepeat response extended into the 123 memory phase (Fig 1Ciii) . 124 125
Increasing anti-CSP precursor B cell number does not supress responses to other antigens 126 127
A previous study highlighted the fact that increasing the number of precursors for an antigen 128 led to a concomitant increase in the number of cells entering GCs; the same study also 129 highlighted roles for antigen valency in allowing responses to successfully compete in the GC 130 (22). To investigate the roles of precursor number and antigen valency we developed a 131 system in which we could modulate the number of precursors or the valency of two 132 competing antigens in the context of CSP. We achieved this by conjugating the 4-hydroxy-3-133 nitrophenyl (NP) acetyl-hapten to recombinant CSP via crosslinking on lysine. Since lysine 134 residues are not found in the CSP repeat region, the NP-hapten would bind exclusively to the 135 N and C terminal domains ( Fig. S3A ). For these experiments we used a slightly truncated 136 CSP molecule carrying 27 repeats (3NVDP and 24 NANP), designated CSP27 ( Fig S1) . As 137 proof of principle we found that immunization with CSP27 conjugated to 2 NP moieties 138 (CSP27-NP2) was able to induce strong anti-NP and anti-CSPRepeat IgG responses ( Fig. S3 ). 139
We were then able to modulate the number of precursors for CSPRepeat-specific B cells using 140 To determine the role of precursor number in driving immunodominance we adoptively 147 transferred defined numbers of CSPRepeat tetramer + , CD45.1 Igh g2A10 cells into CD45.2 148 C57BL/6 mice ( Fig. S2B ). Mice were then immunized with CSP27-NP2, IgG responses were 149 measured 7,14 and 21 days post immunization, and the number of NP and CSPRepeat specific 150 cells were quantified by flow cytometry on day 21 ( Fig. 2A ). We hypothesized that increased 151 anti-CSPRepeat precursor number would not only increase the response to the CSPRepeat but also 152 suppress the NP immune response. As expected, increasing the number of CSPRepeat-specific 153 precursors increased the total number of CSPRepeat binding B cells and CSPRepeat-specific GC 154 B cells responding to this antigen ( Fig. 2B and C). Perhaps surprisingly, the magnitude of the 155 antibody response was unaltered ( Fig. 2D ). However, there was no concomitant decrease in 156 the overall B cells and GC B cell response to NP ( Fig. 2B-C) , and the magnitude of the IgG 157 antibody response to NP was also unaffected by the addition of Igh g2A10 cells ( Fig. 2E ). 158
Finally, because we could distinguish our transferred cells from the endogenous response by 159 the expression of CD45.1, we were able to determine that the endogenous response to CSP 160 was not supressed by the addition of enhanced number of germline precursors specific for 161 CSP ( Fig 2F) . 162
163
We also performed the converse experiment and altered the number of anti-NP precursors 164 relative to the number of CSPRepeat specific cells via the addition of B1-8 hi cells (Fig. S2C ). 165
Notably, B1-8 hi cells differ from Igh g2A10 cells not only in their specificity but also because 166 they carry the high affinity mature Ighv1-72 heavy chain that confers strong binding to NP. 167
Nonetheless, in agreement with the previous experiment, antibody titres to the CSPRepeat were 168 generally unaffected by the transfer of additional naive B-18 hi cells ( Fig S4A) , while 169 increasing the number of NP cells had no significant effect on the number of CSPRepeat 170 specific B cells responding and becoming GC B cells ( Figure S5B -D). However, in contrast 171 to the previous experiment, the additional of B1-8 hi cells did not increase the overall 172 magnitude of the antigen specific B cell and GC response to NP itself; rather, the transferred 173 high affinity B1-8 hi B cells displaced the endogenous cells from the response though this 174 effect rapidly saturated after the transfer of just 1x10 4 B1-8 hi cells ( Fig S4E) . Again, in 175 contrast to the previous experiment, this displacement resulted in higher titres of antibodies 176 targeting NP overall, perhaps due to the high affinity of the transferred cells ( Fig. S4F ). 177
178
Reducing the valency of immunodominant antigens allows subdominant responses to expand 179 180 Given the repeating nature of the CSPRepeat we next tested whether the ability of long CSP 181 molecules to crosslink multiple B cell receptors (BCRs) might drive the immunodominance 182 of this domain. Accordingly, we developed a construct that carried just 9 NANP repeats 183 (CSP9; Fig. S1 ). Using a surface plasmon resonance saturation experiment, we found that 184 CSP9 could only bind 2-3 2A10 antibodies, compared to the 5-6 bound by CSP27, which is 185 in line with previous structural and biophysical data from our laboratory ( Fig. 3A) . 186 Importantly, this reduced binding corresponded to a reduction in BCR signalling as calcium 187 fluxes were lower when Igh g2A10 cells were pulsed with CSP9 compared to CSP27 ( One prediction of our data is that immunization CSP9 will induce stronger responses to the 217 CSPNterm and CSPCterm compared to CSP27. Moreover, if these non-CSPRepeat responses have 218 anti-parasitic effect then immunization with CSP9 should be more protective than 219 immunization with CSP27. Accordingly, we immunized mice 3 times at 5-week intervals 220 with CSP9 and CSP27 formulated in alum before challenging mice with Pb-PfSPZ via 221 mosquito bites 5 weeks after the final immunization ( Fig. 4A ). We also included an 222 additional group which were immunized with CSP9NVDP -a recombinant protein which also 223 had a 9-mer repeat but included 3 NVDP repeats ( Fig. S1 ) -as it has been suggested that 224 (NANPNVDP)n binding antibodies might confer superior protection to pure (NANP)n 225 binding antibodies (13). 226 227 Overall, IgG responses to PfCSP (as measured via ELISA on CSP27 coated plates) were 228 similar in magnitude across all immunized groups (Fig. 4B ). Because differences between 229 immunized mice and control mice are large (as are differences between pre-immune and 230 post-immune sera), but not of particular interest, this group was removed from subsequent 231 analysis as was the pre-immune timepoint to avoid skewing the statistical models. 232
Examination of the specificity of the IgG responses at the domain level revealed significant 233 differences in responses to the different immunogens: CSP9 and CSP9NVDP induced 234 significantly stronger IgG responses to CSPNterm and CSPCterm compared to CSP27 while 235 responses to the repeat were similar ( Figure 4C and D). We also performed more specific 236
ELISAs with peptides corresponding to the regions bound by 5D5 and the CSPNterm/CSPRepeat 237 junction ( Fig. S6A ). We found that the truncated CSP9 and CSP9NVDP induced stronger 238 responses to the 5D5 peptide which lies within the CSPNterm ( Fig S6B) but that responses to 239 the junction peptide were similar across all immunogens ( Fig. S6C) . Surprisingly, while 240
CSPRepeat specific antibody responses were initially lower in CSP9 immunized mice 241 compared to CSP27 immunized mice, the repeat specific responses were similar after the 242 third dose (Fig. 4E) . Nonetheless, the ratio of antibody titres to the CSPNterm and CSPCterm 243 domains to the CSPRepeat domains were significantly higher in the CSP9 immunized mice 244 compared to CSP27 immunized mice at the time of challenge ( Fig 4F and G) . 245 246 Forty-two hours after mosquito bite challenge, livers were excised from the mice and the 247 parasite burden measured by RT-PCR. Both CSP9 and CSP27 induced significant reductions 248 in the mean parasite burden in the liver, whilst CSP9NVDP did not (p = 0.069; Fig. 4H ). 249
Overall 10/11 (91%) control mice had detectable parasite 18SRNA, compared to only 5/15 250 (33%) CSP9 immunized mice which was statistically significant (p=0.005 by Fisher's exact 251 test; Fig. 4I ). In both CSP27 and CSP9NVDP, 9/15 (60%) mice had detectable parasite RNA, 252 which was not significantly different the control group (p=0.17 by Fisher's exact test; Fig.  253 4I). The failure of CSP9NVDP to induce better protection than the CSP9 was surprising to us, 254 but did not reflect a failure to induce NVDP binding antibodies as these antibodies were 255 significantly higher in both CSP27 (which includes NVDP repeats) and CSP9NVDP 256 immunized mice than in the CSP9 immunized mice ( precursors specific for a particular antigen (reviewed in (32)). A common strategy for 279 enhancing antibody responses is to generate polyvalent antigens, such as virus-like particles, 280 to enhance immunity (33). Accordingly, we investigated how the multivalent nature of the 281 CSPRepeat affects the response to this epitope. Our finding that reducing the length of the CSP 282 repeat allows responses to other antigens to develop suggests that not only does the long 283 repeat drive a large response to this antigen itself, but also allows it to supress other 284 responses. The discovery of this "immunodomination" effect provides direct support for the 285 decoy hypothesis, though the exact mechanism for this effect is unclear. Our observation that 286 CSP27 drives stronger BCR signalling than CSP9 suggests that this antigen may drive 287 stronger expansion of the B cell response at the outset. An alternative -non-mutually 288 exclusive hypothesis -is that is that CSP molecules carrying long repeats may be readily 289 taken up by CSPRepeat specific B cells, allowing these B cells to outcompete CSPNterm and 290
CSPCterm specific B cells for T cell help (34, 35) . In agreement with this, it has been 291 previously shown that competition for restricted T cell help can supress responses to rare or 292 subdominant epitopes (36). 293
294
We also investigated the roles of the number of antigen-specific precursors in determining the 295 magnitude of the resulting immune response. The number of naïve precursors specific for a 296 particular epitope was identified as a possible driver of CD4 + and CD8 + T cell 297 immunodominance in mice in studies with peptide immunization or vesicular stomatitis virus 298 infection (37, 38). However, other studies in humans (with HIV and hepatitis B virus) and 299 mice (with influenza A virus) have not reported as strong a relationship as initially reported 300 (39-41), perhaps due to compensation by other factors such as the affinity of the T cell 301 receptor-MHC peptide interaction (32). In agreement with a previous study on the 302 relationship between B cell precursor number and the subsequent GC response (22), we 303 found that artificially increasing the number of precursors by transferring knock-in germline 304 B specific for the CSPRepeat cells did increase the magnitude of the GC response to this 305 epitope. However, surprisingly, this enhanced response did not occur at the expense of 306 responses to other epitopes and did not result in a significantly enhanced antibody response. 307
One reason for the lack of immunodomination after the transfer of large numbers of CSPRepeat 308 specific B cells may be that precursor B cells for the competing antigen in this system (NP) 309 are in excess. In agreement with this, NP specific B cells are reported to be present at high 310 frequency (~1/4000) in C57BL/6 mice (42). Thus, it will thus be important to determine if the 311 same effect is seen when the number of precursors for the subdominant epitope is limiting. 312 313 Interest in developing "universal" vaccines for viruses such as influenza and HIV has led to 314 increased focus on manipulating immunodominance hierarchies. This is because responses to 315 conserved influenza epitopes (such as the HA stem) or conserved targets of bnAbs are 316 subdominant. For HIV there is strong interest in developing multivalent immunogens 317 targeting rare bnAb germline precursors to enhance the frequency of these cells (43, 44). For 318 influenza, a possible vaccine strategy is to develop HA immunogens lacking the 319 immunodominant, but variable head domain (23). One approach that might be possible, based 320 upon studies in model systems would be to delete B cells specific for non-protective epitopes 321 by injecting pure epitopes not linked to a T cell epitope (45). For CSP based malaria vaccines 322 it is probably not desirable to remove the responses to the repeat altogether as antibodies 323 targeting this domain are clearly protective, however a rebalancing of the immune response 324 may be desirable. The current RTS,S vaccine may benefit from having a truncated repeat (of 325 only 18 NANP moieties), though -critically -it lacks the CSPNterm domain and does not have 326 any NVDP repeats (46). Perhaps surprisingly, we did not find that mice which mounted 327 stronger responses to the NANPNVDP repeats were better protected than those which had 328 responses more focussed on pure NANP repeats. This is despite the fact that mAbs that are 329 strongly cross-reactive between both repeat motifs have been shown to protect against 330 Single cell preparations of lymphocytes were isolated from the spleen of immunized mice 365 and were stained for flow cytometry or sorting by standard procedures. Cells were stained 366 with antibodies as outlined in Table S1 and CSP domain specific tetramers conjugated to PE 367 or APC. Tetramers were prepared in house by mixing biotinylated (NANP)9 peptide with 368 streptavidin conjugated PE or APC (Invitrogen) in a 4:1 molar ratio. Flow-cytometric data 369 was collected on a BD Fortessa flow cytometer (Becton Dickinson) and analyzed using 370 
